Trial record 1 of 7 for:    michael boeckh
Previous Study | Return to List | Next Study

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (GRAIL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Fred Hutchinson Cancer Research Center
National Heart, Lung, and Blood Institute (NHLBI)
Genentech, Inc.
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center Identifier:
First received: April 13, 2011
Last updated: February 22, 2016
Last verified: February 2016

To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.

Primary Hypotheses:

- In CMV seropositive adults with severe sepsis or trauma , pulmonary and systemic CMV reactivation amplifies and perpetuates both lung and systemic inflammation mediated through specific cytokines, and contributes to pulmonary injury and multiorgan system failure,


- Prevention of CMV reactivation with ganciclovir decreases pulmonary and systemic inflammatory cytokines that are important in the pathogenesis of sepsis and trauma related complications.

Condition Intervention Phase
Acute Lung Injury
Acute Respiratory Distress Syndrome
Respiratory Failure
Drug: IV Ganciclovir
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)

Resource links provided by NLM:

Further study details as provided by Fred Hutchinson Cancer Research Center:

Primary Outcome Measures:
  • Serum IL-6 level [ Time Frame: at 14 days post-randomization ] [ Designated as safety issue: No ]
    Change between baseline and 14 days post-randomization between placebo & ganciclovir groups

Secondary Outcome Measures:
  • Incidence of CMV reactivation at 28 days (blood, throat) [ Time Frame: at 28 days post-randomization ] [ Designated as safety issue: No ]

    The following virologic parameters will be compared between the groups:

    • Time to CMV reactivation at any level
    • Time to > 1,000 copies per mL
    • Time to > 10,000 copies per mL
    • Area under the curve
    • Peak viral load
    • Initial viral load

  • Additional cytokine levels [ Time Frame: at 7 and 28 days post-randomization ] [ Designated as safety issue: No ]

    Additional cytokines with proven association with ALI and CMV will be compared between the groups.

    • BAL levels of IL-6, IL-8, TNF-alpha & TGF-β
    • Plasma IL-6, IL-8, IL-10, TNF-alpha & soluble ICAM-1

    Cytokines will be analyzed at each time point and over time (area under the curve), and peak levels will be compared between randomization and Day 28 (end of treatment).

  • Clinical outcomes [ Time Frame: at 7, 14, 28, 60, and 180 days post-randomization ] [ Designated as safety issue: No ]
    • Organ system failure at 14 and 28 days
    • Duration of mechanical ventilation (as assessed by ventilator days and ventilator-free days alive)
    • Lung injury score
    • Bacteremia and/or fungemia
    • Mortality at 60 and 180 days after randomization
    • Composite of survival status, ventilation status, and IL-6 levels
    • Subset analysis of laboratory and clinical outcomes amongst subjects who survive at least 7 days after randomization
    • Subset analysis of laboratory and clinical outcomes amongst subjects who are mechanically ventilated for at least 7 through 14 days after randomization

  • Length of stay [ Time Frame: by 28 and 180 days post-randomization ] [ Designated as safety issue: No ]
    • ICU (days alive and not in the ICU by day 28)
    • Hospital (days alive and not hospitalized by day 28 and 180)

  • CMV disease [ Time Frame: by 180 days post-randomization ] [ Designated as safety issue: No ]
    Need to be biopsy-proven

  • Safety [ Time Frame: by 35 days post-randomization ] [ Designated as safety issue: Yes ]
    • Number and severity of AEs and SAEs as defined in the Adverse Event section of the protocol
    • Time to neutropenia (absolute neutrophil count [ANC] < 1000, <500 per mm3)
    • Use of G-CSF
    • Time to renal insufficiency (creatinine clearance < 60, < 30 ml/min)
    • Time to thrombocytopenia (platelet count < 50,000, < 20,000 per mm3)
    • Number of red cell and platelets products between randomization and day 35 after randomization

  • Functional assessment [ Time Frame: at 1 and 180 days post-randomization ] [ Designated as safety issue: No ]
    Patient survey

Estimated Enrollment: 160
Study Start Date: September 2011
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IV Ganciclovir Drug: IV Ganciclovir
For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
Placebo Comparator: Placebo Drug: Placebo

For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.

The placebo is an IV solution that does not contain any active medications.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject/next of kin informed consent
  2. Age >= 18 years
  3. CMV IgG seropositive. The following tests are acceptable:

    • FDA licensed test in a local lab approved by the coordinating center (FHCRC, Seattle, WA).
    • Test in central study lab (ARUP, Salt Lake City, UT)
    • A report that patient has previously been tested and found to be CMV seropositive at any time (a credible next of kin report is acceptable; confirmatory test will be done but results are not required for randomization)
  4. Intubated and requiring mechanical positive pressure ventilation (including Acute Lung Injury/ARDS (EA Consensus Definition))
  5. Meets criteria for either:

    1. Severe sepsis criteria (as defined in appendix G) within a 24-hour time period within the 120 hour window


    2. Trauma with respiratory failure and an ISS score > 15 within a 24 hour time period, and within the 120 hour window (where mechanical ventilation is not due solely to a head injury)
  6. On the day of randomization (by local criteria):

    • Not eligible for SBT (use of sedation and/or vasopressor does not specifically contraindicate SBT),or
    • Failed SBT

Exclusion Criteria:

  1. BMI > 60 (1st weight during hospital admission)
  2. Known or suspected immunosuppression, including:

    • HIV+ (i.e. prior positive test or clinical signs of suspicion of HIV/AIDS; a negative HIV test is not required for enrollment)
    • stem cell transplantation:

      • within 6 months after autologous transplantation or
      • within 1 years after allogeneic transplantation (regardless of immunosuppression)
      • greater than 1 year of allogeneic transplantation if still taking systemic immunosuppression or prophylactic antibiotics (e.g. for chronic graft versus host disease)

    Note: if details of stem cell transplantation are unknown, patients who do not take systemic immunosuppression and do not take anti-infective prophylaxis are acceptable for enrollment and randomization.

    • solid organ transplantation with receipt of systemic immunosuppression (any time).
    • cytotoxic anti-cancer chemotherapy within the past three months (Note: next-of-kin estimate is acceptable).
    • congenital immunodeficiency requiring antimicrobial prophylaxis (e.g. TMP-SMX, dapsone, antifungal drugs, intravenous immunoglobulin).
    • receipt of one or more of the following in the indicated time period:

      • within 6 months: alemtuzumab, antithymocyte/antilymphocyte antibodies
      • within 3 months: immunomodulator therapy (TNF-alpha antagonist, rituximab, tocilizumab, IL1 receptor antagonist and other biologics)
      • within 30 days:

        • corticosteroids > 10 mg/day (chronic administration, daily average over the time period)

          • topical steroids are permissible
          • use of hydrocortisone in "stress doses" up to 100 mg four times a day (400mg/daily) for up to 4 days prior to randomization is permissible
          • use of temporary short-term (up to 2 weeks) increased doses of systemic steroids (up tp 1 mg/kg) for exacerbation of chronic conditions are permissible.
        • methotrexate (> 10.0 mg/week)
        • azathioprine (> 75 mg/day)

    Note: if no information on these agents is available in the history and no direct or indirect evidence exists from the history that any condition exists that requires treatment with these agents (based on the investigator's assessment), the subject may be enrolled. For all drug information, next-of-kin estimates are acceptable. See Appendix D for commonly prescribed immunosuppressive agents.

  3. Expected to survive < 72 hours (in the opinion of the investigator)
  4. Has been hospitalized for > 120 hours (subjects who are transferred from a chronic care ward, such as a rehabilitation unit, with an acute event are acceptable).
  5. Pregnant or breastfeeding (either currently or expected within one month).

    Note: for women of childbearing age (18-60 years, unless documentation of surgical sterilization [hysterectomy, tubal ligation, oophorectomy]), if a pregnancy test has not been done as part of initial ICU admission work-up, it will be ordered stat and documented to be negative before randomization. Both urine and blood tests are acceptable.

  6. Absolute neutrophil count < 1,000/mm3 (if no ANC value is available, the WBC must be > 2500/mm3)
  7. Use of cidofovir within seven (7) days of patient randomization. The use of the following antivirals is permitted under the following conditions:

    • Ganciclovir, foscarnet, high-dose acyclovir, or valacyclovir until the day of randomization
    • Acyclovir as empiric therapy for central nervous system HSV or VZV infection until the diagnosis can be excluded
    • For enrolled patients during the active study drug phase, acyclovir, famciclovir, valacyclovir for treatment of HSV or VZV infection as clinically indicated.
  8. Currently enrolled in an interventional trial of an investigational therapeutic agent known or suspected to have anti-CMV activity, or to be associated with significant known hematologic toxicity (Note: confirm eligibility with one of the study medical directors at the coordinating site).
  9. At baseline patients who have both a tracheostomy, and have been on continuous 24-hour chronic mechanical ventilation.
  10. Patients with Child Class C Cirrhosis.
  11. Patients with pre-existing interstitial lung disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01335932

Contact: Michael Boeckh, MD 206-667-6706
Contact: Ajit Limaye, MD 206-598-1041

United States, Colorado
University of Colorado / National Jewish Health / Swedish Medical Center Recruiting
Denver, Colorado, United States, 80206
Contact: Stephen K Frankel, MD    303-398-1521   
Contact: Carrie Higgins    720-323-2038   
Sub-Investigator: Marc Moss, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Richard W. Wunderink, MD    614-293-4925   
Contact: Helen K. Donnelly, RN, BS, CCR   
United States, Massachusetts
Baystate Critical Care Medicine / Tufts University School of Medicine Completed
Springfield, Massachusetts, United States, 01199
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109-5360
Contact: Robert Hyzy, MD    734-936-5201   
Contact: Kristine Nelson   
Sub-Investigator: Pauline Park, MD         
United States, North Carolina
Wakeforest University, School of Medicine Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Peter Morris, MD    336-716-1210   
Contact: Lori Flores    336-716-1465   
Sub-Investigator: Shayn Martin, MD         
United States, Ohio
The Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Duncan Hite, MD    216-445-5765   
Contact: Michelle Ferrari, RN   
Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Matthew Exline, MD    614-293-4925   
Contact: Jan Drake    614-247-7707   
Sub-Investigator: James O'Brien, MD         
United States, Oregon
The Oregon Clinic Completed
Portland, Oregon, United States, 97220
United States, Pennsylvania
University of Pennsylvania Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19104-6160
Contact: Mark Mikkelsen, MD    215-615-5416   
Contact: Ethan Nguyen    215-614-0628   
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15261
Contact: Scott Gunn, MD    412-958-8398   
Contact: Pamela Fazio, RN    412-864-2069      
Principal Investigator: Scott Gunn, MD         
United States, Vermont
University of Vermont College of Medicine Recruiting
Burlington, Vermont, United States, 05405
Contact: Polly Parsons, MD    802-847-6177   
Contact: Sara Ardren   
Principal Investigator: Renee Stapleton, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908-0546
Contact: Kyle Enfield, MD, MS    434-924-5219   
Contact: Mary Marshall    434 924 2804   
United States, Washington
Harborview Medical Center Recruiting
Seattle, Washington, United States, 98104
Contact: Joseph Cuschieri, MD    206-744-6448   
Contact: Laura Hennessy, RN    206-744-7723   
University of Washington Medical Center / Harborview Medical Center Recruiting
Seattle, Washington, United States, 98195
Contact: Ajit Limaye, MD    206-598-1041   
Contact: Michaela Kusumi, BS    206-598-1810   
Sub-Investigator: Robert Rakita, MD         
Sub-Investigator: Michael Boeckh, MD         
Sub-Investigator: Paul Pottinger, MD         
Canada, Ontario
Sunnybrook Health Sciences Centre Withdrawn
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Heart, Lung, and Blood Institute (NHLBI)
Genentech, Inc.
Principal Investigator: Michael Boeckh, MD Fred Hutchinson Cancer Research Center
Principal Investigator: Ajit Limaye, MD University of Washington
  More Information

Responsible Party: Fred Hutchinson Cancer Research Center Identifier: NCT01335932     History of Changes
Other Study ID Numbers: 7217  U01HL102547 
Study First Received: April 13, 2011
Last Updated: February 22, 2016
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by Fred Hutchinson Cancer Research Center:
Acute Lung Injury
Acute Respiratory Distress Syndrome
Respiratory Failure
Cytomegalovirus seropositive
Intravenous Ganciclovir

Additional relevant MeSH terms:
Acute Lung Injury
Lung Injury
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Respiratory Insufficiency
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Diseases
Respiration Disorders
Respiratory Tract Diseases
Thoracic Injuries
Wounds and Injuries
Ganciclovir triphosphate
Anti-Infective Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors processed this record on May 26, 2016